Page 25 - Demo
P. 25
Subsequent Therapies
Patients with ≥ 1 treatment Anti-metabolitea Platinum compound Anti-neoplastic agent NEC Cytotoxic antibiotic (i.e., anthracycline) Alkylating agent Taxane Vinca alkaloid Immune checkpoint inhibitorb Angiogenesis inhibitor
5%
Atezolizumab + nab-paclitaxel (n = 451)
Placebo
+ nab-paclitaxel (n = 451)
61%
42%
27%
18%
15%
11%
8%
6%
4%
4%
65%
45%
27%
22%
21%
16%
12%
8% 6%
70 60 50 40 30 20 10 0 10 20 30 40 50 60 70
NEC, not elsewhere classified.
Data cutoff: January 2, 2019. Presented data limited to therapies received by ≥ 5% of patients in any treatment arm. a Includes capecitabine, Incidence (%) gemcitabine, gemcitabine hydrochloride, fluorouracil, methotrexate, cytarabine, decitabine, floxuridine, methotrexate sodium, pemetrexed,
tegafur. b Includes monoclonal antibodies targeting PD-L1, PD-1 and CTLA-4.
